Diabetic Macular Edema – Every Letter Matters, Every Day Highlights from Bayer’s Satellite Symposium ‘Eylea® (aflibercept solution for injection) for Visual Impairment due to Diabetic Macular Edema: Every Letter Matters, Every Day,’ held on September 18, 2015, at the 15th EURETINA Congress, Nice, France. Chair: Ian Pearce This supplement is a write-up of a promotional meeting organized and funded by Bayer. The speakers were paid honoraria toward this meeting. Bayer checked the content for factual accuracy, to ensure it is fair and balanced, and that it complies with the ABPI Code of Practice. The views and opinions of the speakers are not necessarily those of Bayer or the publisher. No part of this publication may be reproduced in any form without the permission of the publisher.
Articles:
The Current Treatment Landscape For Visual Impairment due to DMEIan Pearce, Consultant Ophthalmologist, Royal Liverpool University Hospital, Liverpool, UK Aflibercept: Robust, Durable Efficacy in Visual Impairment due to Diabetic Macular Edema
Peter Kaiser, Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio Beyond VEGF: The Role of PlGF in Diabetic Retinopathy
William Li, President and Medical Director, The Angiogenesis Foundation, Boston, USA Assessing the Treatment Landscape in Diabetic Macular Edema: The Place of Aflibercept
Peter Kaiser, Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio Prescribing information can be found on the back cover of the pdf below.
